Candel Therapeutics, Inc. CADL Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s change in deferred revenue?
- Candel Therapeutics, Inc. (CADL) reported change in deferred revenue of -$22K in Q1 2026.
- How has Candel Therapeutics, Inc.'s change in deferred revenue changed year-over-year?
- Candel Therapeutics, Inc.'s change in deferred revenue decreased by 149.4% year-over-year, from $44.5K to -$22K.
- What is the long-term trend for Candel Therapeutics, Inc.'s change in deferred revenue?
- Over 3 years (2021 to 2025), Candel Therapeutics, Inc.'s change in deferred revenue has grown at a 12.5% compound annual growth rate (CAGR), from -$125K to $178K.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.